沙粒病毒的抗病毒药物-猫眼课题宝

沙粒病毒的抗病毒药物

批准号：

8513254

负责人：

SEAN M AMBERG

金额：

$136.49万

依托单位：

SIGA TECHNOLOGIES, INC.

依托单位国家：

美国

项目类别：

财政年份：

2011

资助国家：

美国

项目状态：

已结题

起止时间：

2011-08-17 至 2014-07-31

来源：

https://reporter.nih.gov/project-details/8513254

关键词：

Animal Model Animals Antiviral Agents Arenavirus Binding Biological Biological Availability Categories Cavia Chemicals Chemistry Clinical Data Development Dose Drug Interactions Drug Kinetics Drug resistance Evaluation Foundations Genetic Genetic Determinism Glycoproteins Goals Human In Vitro Investigational New Drug Application Junin virus Lassa Fever Lassa virus Lead Libraries Macaca fascicularis Metabolism Modeling Monitor Mutation Organ Pharmaceutical Chemistry Pharmaceutical Preparations Pharmacology Pharmacology and Toxicology Predisposition Preparation Proteins Reporting Resistance Ribavirin Safety Series Solubility Specificity Structure Structure-Activity Relationship Tacaribe Complex Viruses Testing Toxic effect Toxicology Variant Viral Viral Hemorrhagic Fevers Virus analog analytical method animal efficacy base chemical synthesis cost effective drug metabolism drug resistant virus efficacy evaluation fitness genotoxicity hemorrhagic fever virus in vivo inhibitor/antagonist large scale production nonhuman primate pharmacophore pre-clinical prevent programs protective efficacy screening small molecule

项目摘要

项目成果

SEAN M AMBERG的其他基金

相似基金

相关文献

中文摘要

翻译

描述(由申请人提供)：这里描述的计划的目标是开发一种治疗和预防拉沙热和其他由阿拉伯病毒引起的出血热的抗病毒药物。先前的文库筛选发现了几个很好的拉萨病毒进入的候选小分子抑制剂。随后的体外和体内鉴定确定了一个有效的系列，ST-193，对5种不同的A类出血热病毒具有广谱活性。该系列已在两种拉沙热动物模型--豚鼠和食蟹猴身上显示出保护效果。本申请的具体目标是优化这一化学系列，以确定临床前开发的合适候选者，并收集必要的数据，以支持提交研究新药(IND)的申请。

英文摘要

DESCRIPTION (provided by applicant): The goal of the program described here is to develop an antiviral drug for treating and preventing Lassa fever and other hemorrhagic fevers of arenavirus origin. Previous library screening identified several good candidate small molecule inhibitors of Lassa virus entry. Subsequent in vitro and in vivo characterization identified a potent series, ST-193, with broad- spectrum activity against 5 distinct Category A hemorrhagic fever Arenaviruses. This series has shown protective efficacy in two animal models of Lassa fever, guinea pigs and cynomolgus monkeys. The specific objective of this application is to optimize this chemical series to identify an appropriate candidate for preclinical development and to collect the necessary data to support the submission of an application for an Investigational New Drug (IND).

期刊论文(0)

专著(0)

科研奖励(0)

会议论文